July 23rd 2025
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Expert Insights: Most Popular Videos, Interviews, and Podcasts in 2016
Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care
How Can Practices Seek Success With Oncology Payment Reform?
Preventing Chemotherapy-Associated Alopecia: A Case for Palliation?
Smoking Cessation Programs Need a Boost Under Medicaid Expansion